Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Hyperlipidemias

imatinib mesylate has been researched along with Hyperlipidemias in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguiar, JM; Brümmendorf, TH; Cortes, JE; Dimitrov, S; Durand, JB; Fly, KD; Gambacorti-Passerini, C; Jean Khoury, H; Kantarjian, H; Leip, E; Lipton, JH; Matczak, E; Mauro, MJ; Pavlov, D; Shapiro, M1
Gherlinzoni, F; Gottardi, M; Manzato, E1

Trials

1 trial(s) available for imatinib mesylate and Hyperlipidemias

ArticleYear
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
    American journal of hematology, 2016, Volume: 91, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aniline Compounds; Cardiotoxicity; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Risk Factors; Vascular Diseases; Young Adult

2016

Other Studies

1 other study(ies) available for imatinib mesylate and Hyperlipidemias

ArticleYear
Imatinib and hyperlipidemia.
    The New England journal of medicine, 2005, Dec-22, Volume: 353, Issue:25

    Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2005